CD8A and neoplasm: In renal cell carcinoma, a combination therapy using bev to inhibit VEGF and atezo to inhibit PD-L1 increased the number of CD8+ T cells in the tumor tissue; increased MHC-1, Th1, and T effector markers; and improved the migration of antigen-specific T cells [107].